| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and maintains $...
Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticip...
B. Riley Securities analyst Madison El-Saadi initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy rating and...
Cantor Fitzgerald analyst Olivia Brayer maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Overweight and lowers the price...
Vanda Pharmaceuticals (NASDAQ:VNDA) narrows FY2025 sales outlook from $210.000 million-$250.000 million to $210.000 million-$23...